Once-a-day pill to beat alcoholism gains backing from health officials
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A once-a-day pill to help alcoholics quit drinking has won the backing of health officials in England.
Nalmefene, which is already used in Scotland, helps people cope with the craving for alcohol by reducing the “buzz” they get from drinking.
Nearly 600,000 people could benefit from the drug, according to the National Institute for Health and Care Excellence (NICE), which said in draft guidance published today that nalmefene should be available as an option. Treating that number of people would cost about £600m a year.
Professor Carole Longson, of NICE, said: “Alcohol addiction is a serious issue for so many. Those who could be prescribed nalmefene have already taken the first big steps in their fight against their addiction by visiting their doctor and taking part in therapy programmes.”
She added: “When used alongside psychosocial interventions, nalmefene is clinically and cost effective for the NHS compared with psychosocial interventions alone.”
NICE said nalmefene “should only be prescribed in conjunction with continuous psychosocial support”.
A consultation period on the idea of offering nalmefene on the NHS is now open and the final guidance is expected in November. A separate decision will be taken by the authorities in Wales and Northern Ireland.
Scotland became the first European country to prescribe nalmefene in October last year after trials showed some success. Men who usually drank eight units a day and women who drank six a day cut those amounts by half while taking the drug over six months.
However, Dr Des Spence, a GP in Glasgow, wrote an article in the British Medical Journal in February criticising the decision to give nalmefene on the NHS in Scotland at a cost of £84 a month per patient and casting doubt on the significance of the trial findings.
“Surely these resources would be better spent improving alcohol counselling services?” he wrote. “The drugs in alcohol addiction have tiny benefits and are a distraction from the real challenges of limiting the availability and increasing the cost of alcohol. This bad medicine is all too familiar.”
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments